Resource Library

Tenofovir is less toxic than other nucleoside reverse-transcriptase inhibitors used in antiretroviral therapy (ART) and may improve retention of human immunodeficiency virus (HIV)–infected patients on ART. We assessed the impact of national guideline changes in South Africa (2010) and Zambia (…

Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa are experiencing failure of first-line antiretroviral therapy and transitioning onto second-line regimens. However, there is a dearth of research on their treatment experiences. We conducted in-…

Botswana has among the highest level of HIV viral suppression globally, yet HIV incidence remains > 1% per year in adults aged 15 to 49. Although causes of this continued elevated incidence have been postulated, a firm understanding remains elusive, especially in the presence of a highly…

The Southern African Development Community (SADC) is a region associated with both high rates of population mobility – mostly associated with movement within and across national borders to access improved livelihood opportunities – and a high prevalence of communicable diseases, notably HIV and…

More adolescents and young adults living with HIV are surviving into adulthood. As a result they must transition from pediatric health services to HIV self-management and adult care. This change is particularly important as many young people have poor adherence to treatment, leading to low rates…

Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa are experiencing failure of first-line antiretroviral therapy and transitioning onto second-line regimens. However, there is a dearth of research on their treatment experiences. We conducted in-depth interviews with 43…

Update on recommendations on antiretroviral regimens for treating and preventing HIV infection: In 2016, WHO published the consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and recommended tenofovir disoproxil fumarate (…

BACKGROUND: In Malawi's PMTCT Option B+ program, HIV-infected pregnant women who are already receiving ART are continued on…

Despite progress in many aspects of the global HIV response, women - particularly adolescent girls and young women - continue to be disproportionately affected by HIV. Women constitute more than half of all people living with HIV. AIDS-related illnesses remain the leading cause of death for…

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

This first progress report shows that members of the Global HIV Prevention Coalition have mobilized around strengthening HIV primary prevention. There are clear signs of renewed political commitment and strengthened institutional arrangements for planning and managing prevention programmes. Most…

Over the past two decades, the landscape of medications used to treat HIV has evolved rapidly. Treatment options have improved dramatically with the development and availability of more efficacious, safer, and more tolerable antiretrovirals (ARVs). These options allow national…

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries. WHO guidelines for these regions define failure of ART with a lenient threshold of viraemia (HIV RNA viral…

Innovative approaches are needed to increase engagement in HIV treatment and prevention services, particularly in HIV hot spots. Here, we detail our design, training approach, and early implementation experiences of a community-based HIV intervention called “health scouts.” The intervention,…

The Road Map was prepared through a consultative process that brought together more than 40 countries and organizations, including civil society organizations, networks of people living with HIV, faith-based organizations, networks of key populations and international organizations and…

Background

Strategies to improve the uptake of Prevention of Mother-To-Child Transmission of HIV (PMTCT) are needed. We integrated HIV and maternal, newborn and child health services in a One Stop Clinic to improve the PMTCT…

This report compiles the latest body of evidence on how stigma and discrimination create barriers across the HIV prevention, testing and treatment cascades and reduce the impact of the AIDS response. The report also brings together best practices on confronting stigma and discrimination,…

Adolescents living with HIV are an underserved population, with poor retention in HIV health care services and high mortality, who are in need of targeted effective interventions. We conducted a literature review to identify strategies that could be adapted to meet the needs of adolescents…

The life expectancy of HIV-positive individuals receiving antiretroviral therapy (ART) is approaching that of HIV-negative people. However, little is known about how these populations compare in terms of health-related quality of life (HRQoL). We aimed to compare HRQoL between HIV-positive and…

Approximately 1.4 million women living with HIV become pregnant every year. Most women use antiretroviral therapy, to reduce the risk of vertical transmission or for personal health reasons. Using the GRADE framework according to the BMJ Rapid Recommendation process, we make recommendations for…

This multi-country trial examined outcomes among treatment-naïve adults and children with CD4 counts below 100 who were given enhanced antimicrobial prophylaxis including trimethoprim-sulfamethoxazole, isoniazid-pyridoxine, fluconazole, azithromycin, and albendazole in addition to antiretroviral…

The following information provides guidance to health care providers attending to the medical needs of adults and children with HIV displaced from disaster areas who have not yet secured HIV care in the areas where they have relocated.

If possible, management of antiretroviral therapy…

Hepatitis B virus (HBV)–HIV coinfections are becoming common with information on HBV genetic diversity and drug resistance still remaining elusive. To evaluate the HBV genetic diversity and drug resistance-associated mutations among drug-experienced HIV patients, the genetic analysis of the…

The following abstract was presented as part of a poster dicussion session on viral reservoirs at the 9th IAS Conference on HIV Science (IAS 2017).

Background: In the 6-year CHER trial (2005-2011), HIV-infected infants were randomized to deferred antiretroviral therapy (…

These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in 2015.

Since the release of the previous guidelines, the scale-up of antiretroviral therapy (ART) in southern…

Few low-income countries have virological monitoring widely available. We estimated the virological durability of first-line antiretroviral therapy (ART) after five years of follow-up among adult Ugandan and Zimbabwean patients in the DART study, in which virological assays were conducted…

Objective: The aim of the present study was to determine whether a combination of anti-HIV drugs – tenofovir (TFV), lopinavir (LPV) and ritonavir (RTV) – in a lipid-stabilized nanosuspension (called TLC-ART101) could enhance and sustain intracellular drug levels and exposures in lymph…

Although lifelong combination antiretroviral therapy (ART) is recommended for all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before conception. We assessed adverse pregnancy outcomes associated with ART initiated before conception compared with…